#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Short-bowel syndrome Oesophageal adenocarcinoma stage III Precursor T-lymphoblastic lymphoma/leukaemia recurrent Anti-HLA antibody test positive Sjogren's syndrome Ventricular fibrillation Bronchopulmonary aspergillosis Systemic lupus erythematosus ABO haemolytic disease of newborn Netherton's syndrome Rheumatoid arthritis Lymphangioma Chondrosarcoma Fibrosarcoma Hepatitis B More trials…

    Learn about Rare Diseases

    Paraneoplastic neurological syndrome – Trials in Disease Adrenogenital syndrome – Trials in Disease Focal segmental glomerulosclerosis – Diagnostics KBG syndrome – Diagnostics Haemophilia B with anti factor IX – Basic Information Activated PI3 kinase delta syndrome – Basic Information Ewing’s sarcoma – Diagnostics Primary mediastinal large B-cell lymphoma – Diagnostics Antithrombin III deficiency – Diagnostics Congenital hypotransferrinaemia – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Metoclopramide Hydrochloride Dorzolamide Hydrochloride Loperamide Hydrochloride Mexiletine Hydrochloride Donidalorsen Blu-451 Tramazoline Hydrochloride Ralinepag Vo659 Dexamethasone Base Imatinib Mesilate Povidone DCC-3084 Amlitelimab Zongertinib Minzasolmin Allogeneic Faecal Microbiota Hydrochlorothiazide Ezetimibe Neridronate Sodium More therapies…

    Learn about Your Condition

    Red blood cell abnormality Diminished ovarian reserve Gastrointestinal melanoma Diabetic foot infection Laryngeal cancer stage I Bladder cancer Metastases to liver Hypersomnia Cerebrovascular accident Haemorrhagic stroke Graft infection Tonsillitis Diabetic foot Acquired ATTR amyloidosis Candida infection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Malignant peritoneal neoplasm

  • Comparison of Niraparib alone versus Niraparib with Bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Niraparib
    • Bevacizumab
    • Carboplatin
    Belgium Czechia Germany Italy

  • Study on the Effects of ZN-c3 for Patients with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Aprepitant
    • Azenosertib
    • Fluoxetine Hydrochloride
    Belgium France Italy Poland Spain

  • Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Azenosertib
    • Netupitant
    • Palonosetron
    Belgium France Germany Ireland Italy Poland +1

  • Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Carboplatin
    • Olaparib
    Poland

  • Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cervix carcinoma recurrent
    • Endometrial cancer recurrent
    • Fallopian tube cancer
    Investigated Drugs:
    • Imgn151
    • Prednisolone Acetate
    • Brimonidine Tartrate
    Belgium France Germany Ireland Italy The Netherlands +1

  • Study of Pembrolizumab for Patients with Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Malignant peritoneal neoplasm
    • Ovarian cancer
    Investigated Drugs:
    • Pembrolizumab
    Italy
1 2
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!